TNFRSF1A and psoriasis: The IL-1 inhibitor IL-1RA, the macrophage marker CD163 (a hemoglobin-haptoglobin scavenger), several cytokines and soluble cytokine receptors (CCL2, CCL24, TRAIL, TRAIL-R1, TNF-R1, TNF-R2), the IL-18 inhibitor IL-18BP, the angiogenesis inhibitor GDF-2, cardiovascular disease risk proteins (galectin-3, cathepsin L1, cathepsin D, IGFBP2), as well as mediators of cell adhesion (integrin β2, SLAMF7), apoptosis (FAS, Caspase-8), T cell activation (TREML2), proliferation (AXL), co-stimulation (PD-L2), and humoral immunity (TNFRSF13B) were also increased only in psoriasis.